findmyKOL

Chi-Yuan Hsu, MD

Basic profile

Kaiser Permanente

ORCIDNone on fileNPI
RegionSan Francisco, CA · WestSpecialtyNephrologyFocusNephrology
Active KOLEmergingfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPaymentsNone reportedNIH funding2002–2026Why? →

Chi-Yuan Hsu is a Nephrology physician affiliated with Kaiser Permanente. OpenAlex indexes 19 publications with 287 citations (h-index 4); ClinicalTrials.gov lists 5 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
19publications

Distinct works indexed by OpenAlex.

287citations

Total citations across indexed works.

4h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
5clinical trials

Investigator role on registered studies.

View trials
15NIH grants · 2002–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

513 Parnassus Avenue, Hse 672, Box 0532, Ucsf Nephrolog
San Francisco, Ca 94143-0532
San Francisco, CA 941430532

Telephone

415-476-2172

Registry record last updated 17 Sept 2019.

View the NPPES registry record

Clinical trials

5 registered studies on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    72.8%
    Angiotensin receptor blocker (ARB)13%
    Valsartan58%Irbesartan42%
    Part D<11 patients
    ACE inhibitor11.2%
    Lisinopril55%Benazepril Hcl45%
    Part D<11 patients

    + 6 more classes in this area

  • Metabolism & gastrointestinal

    16.7%
    SGLT2 inhibitor16.7%
    Farxiga54%Jardiance46%
    Part D<11 patients
  • Musculoskeletal

    10.5%
    Xanthine oxidase inhibitor10.5%
    Febuxostat52%Allopurinol48%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

15 NIH research awards on record, funded 20022026 per NIH RePORTER. The latest:

74 more award records behind the reveal.Reveal →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”